Medical Oncology

ASCO 2024

Questions discussed in this category

What are your top takeaways from ASCO GI 2024?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice...

1 Answer available

What are your top takeaways from ASCO GU 2024?

What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical prac...

4 Answers available

Papers discussed in this category

N Engl J Med,

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma.

The Lancet. Oncology, 2023 Sep 12

Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.

Related Topics in Medical Oncology